Peptide p277

Drug Profile

Peptide p277

Alternative Names: AVE-0277; DiaPep-277; DiaPep277

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Andromeda Biotech; DeveloGen
  • Class Antihyperglycaemics; Heat shock proteins; Peptide fragments; Peptide vaccines
  • Mechanism of Action T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Suspended Latent autoimmune diabetes in adults; Type 1 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Jun 2016 Andromeda Biotech completes a phase III extension trial for Type-1 diabetes mellitus in Israel (NCT00644501)
  • 17 Feb 2015 Hyperion CBI and Yeda enter into a final agreement in relation to the development of peptide p277
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top